NCT00570674View on ClinicalTrials.gov

Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Squamous Cell Carcinoma of the Head and NeckBasaloid Squamous Cell CarcinomaUndifferentiated CarcinomaAdenosquamous Cell Carcinoma
Interventions
DRUG

Abraxane

DRUG

Erbitux

DRUG

Carboplatin

RADIATION

Intensity Modulated Radiation Therapy

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT00570674 - Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck | Biotech Hunter | Biotech Hunter